Basilea Pharmaceutica AG (BSLN) - Net Assets
Based on the latest financial reports, Basilea Pharmaceutica AG (BSLN) has net assets worth CHF127.94 Million CHF (≈ $161.75 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF282.00 Million ≈ $356.52 Million USD) and total liabilities (CHF154.06 Million ≈ $194.77 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Basilea Pharmaceutica AG to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF127.94 Million |
| % of Total Assets | 45.37% |
| Annual Growth Rate | 0.09% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 115.14 |
Basilea Pharmaceutica AG - Net Assets Trend (2002–2025)
This chart illustrates how Basilea Pharmaceutica AG's net assets have evolved over time, based on quarterly financial data. See Basilea Pharmaceutica AG defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Basilea Pharmaceutica AG (2002–2025)
The table below shows the annual net assets of Basilea Pharmaceutica AG from 2002 to 2025. For live valuation and market cap data, see market cap of Basilea Pharmaceutica AG.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CHF127.94 Million ≈ $161.75 Million |
+57.95% |
| 2024-12-31 | CHF81.00 Million ≈ $102.40 Million |
+909.75% |
| 2023-12-31 | CHF-10.00 Million ≈ $-12.65 Million |
+51.71% |
| 2022-12-31 | CHF-20.71 Million ≈ $-26.19 Million |
+64.65% |
| 2021-12-31 | CHF-58.61 Million ≈ $-74.10 Million |
+42.57% |
| 2020-12-31 | CHF-102.05 Million ≈ $-129.01 Million |
-9.77% |
| 2019-12-31 | CHF-92.96 Million ≈ $-117.53 Million |
-39.40% |
| 2018-12-31 | CHF-66.69 Million ≈ $-84.31 Million |
-60.92% |
| 2017-12-31 | CHF-41.44 Million ≈ $-52.39 Million |
-18.40% |
| 2016-12-31 | CHF-35.00 Million ≈ $-44.25 Million |
-335.60% |
| 2015-12-31 | CHF14.86 Million ≈ $18.78 Million |
-74.36% |
| 2014-12-31 | CHF57.93 Million ≈ $73.24 Million |
-18.26% |
| 2013-12-31 | CHF70.87 Million ≈ $89.60 Million |
-32.82% |
| 2012-12-31 | CHF105.50 Million ≈ $133.38 Million |
-31.17% |
| 2011-12-31 | CHF153.27 Million ≈ $193.77 Million |
-27.10% |
| 2010-12-31 | CHF210.24 Million ≈ $265.80 Million |
+115.13% |
| 2009-12-31 | CHF97.73 Million ≈ $123.56 Million |
-51.07% |
| 2008-12-31 | CHF199.74 Million ≈ $252.53 Million |
-40.39% |
| 2007-12-31 | CHF335.10 Million ≈ $423.66 Million |
+198.38% |
| 2006-12-31 | CHF112.31 Million ≈ $141.99 Million |
-33.10% |
| 2005-12-31 | CHF167.87 Million ≈ $212.23 Million |
-19.91% |
| 2004-12-31 | CHF209.60 Million ≈ $264.99 Million |
+132.14% |
| 2003-12-31 | CHF90.29 Million ≈ $114.15 Million |
-27.99% |
| 2002-12-31 | CHF125.38 Million ≈ $158.51 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Basilea Pharmaceutica AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 79795709000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CHF13.32 Million | 10.41% |
| Other Comprehensive Income | CHF-3.90 Million | -3.05% |
| Other Components | CHF1.00 Billion | 782.46% |
| Total Equity | CHF127.94 Million | 100.00% |
Basilea Pharmaceutica AG Competitors by Market Cap
The table below lists competitors of Basilea Pharmaceutica AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hunan Huakai Cultural and Creative Co Ltd
SHE:300592
|
$686.38 Million |
|
Lotte Reit Co Ltd
KO:330590
|
$686.38 Million |
|
Lander Sports Development Co Ltd
SHE:000558
|
$686.70 Million |
|
Cita Mineral Investindo Tbk PT
JK:CITA
|
$686.90 Million |
|
Placoplatre SA
PA:MLPLC
|
$685.48 Million |
|
Cryoport Inc
NASDAQ:CYRX
|
$685.47 Million |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
$685.33 Million |
|
SunCoke Energy Inc
NYSE:SXC
|
$684.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Basilea Pharmaceutica AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 80,999,000 to 127,941,000, a change of 46,942,000 (58.0%).
- Net income of 40,200,000 contributed positively to equity growth.
- Share repurchases of 617,000 reduced equity.
- New share issuances of 617,000 increased equity.
- Other comprehensive income increased equity by 839,000.
- Other factors increased equity by 5,903,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CHF40.20 Million | +31.42% |
| Share Repurchases | CHF617.00K | -0.48% |
| Share Issuances | CHF617.00K | +0.48% |
| Other Comprehensive Income | CHF839.00K | +0.66% |
| Other Changes | CHF5.90 Million | +4.61% |
| Total Change | CHF- | 57.95% |
Book Value vs Market Value Analysis
This analysis compares Basilea Pharmaceutica AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.99x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.00x to 4.99x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | CHF24.90 | CHF49.85 | x |
| 2003-12-31 | CHF17.38 | CHF49.85 | x |
| 2004-12-31 | CHF30.15 | CHF49.85 | x |
| 2005-12-31 | CHF22.55 | CHF49.85 | x |
| 2006-12-31 | CHF14.56 | CHF49.85 | x |
| 2007-12-31 | CHF36.92 | CHF49.85 | x |
| 2008-12-31 | CHF20.90 | CHF49.85 | x |
| 2009-12-31 | CHF10.20 | CHF49.85 | x |
| 2010-12-31 | CHF21.88 | CHF49.85 | x |
| 2011-12-31 | CHF15.99 | CHF49.85 | x |
| 2012-12-31 | CHF11.00 | CHF49.85 | x |
| 2013-12-31 | CHF7.30 | CHF49.85 | x |
| 2014-12-31 | CHF5.82 | CHF49.85 | x |
| 2015-12-31 | CHF1.47 | CHF49.85 | x |
| 2016-12-31 | CHF-3.46 | CHF49.85 | x |
| 2017-12-31 | CHF-3.82 | CHF49.85 | x |
| 2018-12-31 | CHF-6.15 | CHF49.85 | x |
| 2019-12-31 | CHF-8.64 | CHF49.85 | x |
| 2020-12-31 | CHF-9.93 | CHF49.85 | x |
| 2021-12-31 | CHF-5.02 | CHF49.85 | x |
| 2022-12-31 | CHF-1.73 | CHF49.85 | x |
| 2023-12-31 | CHF-0.82 | CHF49.85 | x |
| 2024-12-31 | CHF5.85 | CHF49.85 | x |
| 2025-12-31 | CHF9.99 | CHF49.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Basilea Pharmaceutica AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 31.42%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.30%
- • Asset Turnover: 0.82x
- • Equity Multiplier: 2.20x
- Recent ROE (31.42%) is above the historical average (-38.57%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | -47.04% | -28859.30% | 0.00x | 1.20x | CHF-71.51 Million |
| 2003 | -61.64% | -14674.97% | 0.00x | 1.19x | CHF-64.68 Million |
| 2004 | -36.01% | -26324.03% | 0.00x | 1.10x | CHF-96.43 Million |
| 2005 | -29.54% | -162.64% | 0.12x | 1.52x | CHF-66.38 Million |
| 2006 | -75.82% | -1185.30% | 0.04x | 1.81x | CHF-96.38 Million |
| 2007 | -37.84% | -1605.63% | 0.02x | 1.38x | CHF-160.33 Million |
| 2008 | -71.86% | -1198.64% | 0.04x | 1.64x | CHF-163.50 Million |
| 2009 | -123.54% | -450.04% | 0.13x | 2.11x | CHF-130.51 Million |
| 2010 | 51.16% | 93.08% | 0.37x | 1.51x | CHF86.54 Million |
| 2011 | -37.61% | -87.14% | 0.28x | 1.55x | CHF-72.97 Million |
| 2012 | -50.27% | -90.91% | 0.16x | 3.56x | CHF-63.58 Million |
| 2013 | -46.59% | -80.63% | 0.14x | 4.23x | CHF-40.11 Million |
| 2014 | -71.72% | -97.76% | 0.17x | 4.44x | CHF-47.34 Million |
| 2015 | -414.67% | -116.62% | 0.13x | 26.84x | CHF-63.09 Million |
| 2016 | 0.00% | -77.73% | 0.20x | 0.00x | CHF-47.79 Million |
| 2017 | 0.00% | -19.07% | 0.29x | 0.00x | CHF-15.22 Million |
| 2018 | 0.00% | -23.65% | 0.47x | 0.00x | CHF-24.68 Million |
| 2019 | 0.00% | -16.69% | 0.61x | 0.00x | CHF-13.13 Million |
| 2020 | 0.00% | -11.53% | 0.56x | 0.00x | CHF-4.52 Million |
| 2021 | 0.00% | -4.61% | 0.60x | 0.00x | CHF-970.30K |
| 2022 | 0.00% | 8.22% | 0.67x | 0.00x | CHF14.22 Million |
| 2023 | 0.00% | 6.63% | 0.91x | 0.00x | CHF11.45 Million |
| 2024 | 95.80% | 37.21% | 0.81x | 3.18x | CHF69.49 Million |
| 2025 | 31.42% | 17.30% | 0.82x | 2.20x | CHF27.41 Million |
Industry Comparison
This section compares Basilea Pharmaceutica AG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $280,769,419
- Average return on equity (ROE) among peers: -22.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Basilea Pharmaceutica AG (BSLN) | CHF127.94 Million | -47.04% | 1.20x | $686.09 Million |
| Addex Therapeutics Ltd (ADXN) | $16.93 Million | -91.05% | 0.33x | $6.98 Million |
| Bachem Holding AG (BANB) | $359.38 Million | 17.79% | 0.19x | $6.02 Billion |
| BB Biotech AG (BION) | $3.00 Billion | -26.71% | 0.07x | $2.48 Billion |
| Bioversys AG (BIOV) | $59.81 Million | -36.50% | 0.52x | $161.41 Million |
| Idorsia Ltd (IDIA) | $-1.21 Billion | 0.00% | 0.00x | $1.03 Billion |
| MINDMAZE THERAPEUTICS HOLDING SA (MMTX) | $38.34 Million | -25.84% | 0.34x | $56.46 Million |
| Molecular Partners AG (MOLN) | $48.32 Million | 14.78% | 1.28x | $145.86 Million |
| Newron Pharmaceuticals SpA (NWRN) | $67.86 Million | -24.17% | 0.27x | $297.11 Million |
| Relief Therapeutics Holding AG (RLF) | $145.42 Million | -34.93% | 0.30x | $36.33 Million |
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus au… Read more